肺癌脑转移管理迎来个体化治疗时代:我们准备好打破壁垒了吗?
本文综述肺癌脑转移管理的演变,指出肺癌患者中近半数发生脑转移,显著损害生存与生活质量。免疫检查点抑制剂和下一代中枢神经系统穿透性靶向治疗改善了颅内控制与患者结局,立体定向放疗较全脑放疗更精准且安全性更优,但治疗顺序、患者选择和风险适应策略仍存挑战。
要点
- 肺癌患者中近半数发生脑转移,显著损害生存和生活质量。
- 免疫检查点抑制剂和CNS穿透性靶向治疗改善了颅内控制与结局。
- 立体定向放疗较全脑放疗更精准且安全性更优,需个体化整合系统与局部治疗。
核心结论
- 免疫检查点抑制剂和下一代CNS穿透性靶向治疗重塑了肺癌脑转移治疗格局,改善了颅内控制和患者结局。
- 系统与局部治疗的个体化整合为优化CNS疾病控制提供新机会,但治疗顺序、患者选择和风险适应策略仍是关键挑战。
研究设计与样本
- 本文为综述,总结肺癌脑转移管理的演变,并强调未来临床试验设计方向。
主要发现
- 肺癌患者中近半数发生脑转移,显著损害生存和生活质量。
- 历史上血脑屏障穿透有限和系统治疗颅内疗效低限制了治疗选择。
- 免疫检查点抑制剂和下一代CNS穿透性靶向治疗改善了颅内控制和患者结局。
- 立体定向放疗是精准有效的局部治疗,安全性优于全脑放疗。
临床怎么用
- 临床应个体化整合系统治疗与局部治疗以优化CNS疾病控制。
- 需关注治疗顺序、患者选择和风险适应策略。
- 未来临床试验设计应整合临床、生物学和影像学工具以指导个体化治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Brain metastases occur in nearly half of patients with lung cancer and significantly impair survival and quality of life. Historically, limited blood-brain barrier penetration and low intracranial efficacy of systemic therapies restricted treatment options. However, advances in immune checkpoint inhibitors and next-generation central nervous system-penetrant targeted therapies have reshaped the therapeutic landscape, improving intracranial control and patient outcomes. In parallel, stereotactic radiotherapy has emerged as a precise and effective local treatment with a more favorable safety profile than whole-brain radiotherapy. The integration of systemic and local approaches, guided by personalized medicine, offers new opportunities to optimize central nervous system disease control. Nevertheless, these advances raise key challenges regarding treatment sequencing, patient selection, and risk-adapted strategies. This review summarizes the evolving management of lung cancer brain metastases and highlights future directions for clinical trial design, emphasizing the integration of clinical, biological, and radiological tools to guide individualized treatment strategies.
引用
- Mavrikios A, Bortolot M, Le Péchoux C, et al. Lung cancer brain metastases management at the dawn of personalized medicine: are we ready to break the barriers? Ann Oncol. 2026. PMID: 42061818. doi:10.1016/j.annonc.2026.04.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。